DATATRAK Announces a Singular Focus - DATATRAK ONE(TM)

DATATRAK Announces a Singular Focus - DATATRAK ONE(TM)

CLEVELAND, Aug. 5 /PRNewswire-FirstCall/ -- DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, formalized its singular vision for product and service delivery today with the announcement of DATATRAK ONE((TM)). Unlike its competitors, which require integration between disparate systems, the DATATRAK eClinical((TM)) product is the only system built on a single, unified platform. The uniqueness of our technology platform has been expanded throughout the company's service offerings as a concept of "One":

  • One technology
  • One solution
  • One service offering
  • One team
  • One knowledge base
  • One comprehensive set of unified DATATRAK eClinical modules
  • One database
  • One interface
  • One point of access to all trials
  • One username and password
  • One vendor

"DATATRAK ONE((TM)) is the cornerstone of our vision to deliver eClinical excellence," said Laurence Birch, DATATRAK's Interim CEO. "The primary goal of DATATRAK ONE((TM)) is to provide the most complete and comprehensive set of clinical trial solutions to our customers. We will use the concept of DATATRAK ONE((TM)) to provide the market an alternative solution--available today--in which all elements of clinical trial data management are available in ONE easy to use on-line solution compared to the patch-work technologies many of our competitors offer. Our unique alignment of technology and process sets us apart from our competition and increases return on investment for our clients."

DATATRAK ONE((TM)) is further defined in the Company's Letter to Shareholders. Please read the Shareholder Letter found in the 2008 Annual Report for more information on DATATRAK ONE((TM)):http://www.datatrak.net/company/PDF/2008 Annual Report and Form 10-K.pdf

 

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. We operate under the concept of DATATRAK ONE(TM), which encompasses our unique, single platform technology. The singular architecture of our DATATRAK eClinical(TM) product suite has been embraced by clients around the globe for its ability to effectively manage clinical trials through an integrated multi-component, comprehensive solution. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical((TM)) software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

Suggested Articles

Last month, rumors out of Bloomberg whispered that Gilead, more known for its COVID-19 work these days, was gearing up for a major stake in Arcus.

The NGOs think Big Pharma controls the agenda of the IMI, leading it to prioritize areas that are profitable for drugmakers over public health needs.

Scientists at McMaster University and the University of Toronto have formed Empirica Therapeutics to bring a CAR-T for glioblastoma into the clinic.